GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
- Conditions
- HIV-1
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00144833
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, London, United Kingdom
🇮🇹GSK Clinical Trials Call Centre, Torino, Italy
🇬🇧GSK Clinical Trials call Center, Birmingham, United Kingdom
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00140712
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3994
- Registration Number
- NCT00140686
- Locations
- 🇪🇸
GSK Investigational Site, Sodupe (Vizcaya), Spain
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT00140725
- Locations
- 🇭🇰
GSK Investigational Site, Shatin, Hong Kong
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- Biological: GSK Biologicals' 719125
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3
- Registration Number
- NCT00140738
- Locations
- 🇵🇪
GSK Investigational Site, Lima, Peru
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 63227
- Registration Number
- NCT00140673
- Locations
- 🇻🇪
GSK Investigational Site, Valencia, Carabobo, Venezuela
A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00139334
- Locations
- 🇧🇩
GSK Investigational Site, Dhaka, Bangladesh
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6360
- Registration Number
- NCT00139347
- Locations
- 🇵🇦
GSK Investigational Site, Panama, Panama
Michelangelo - Oasis 5
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20078
- Registration Number
- NCT00139815
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT00137930
- Locations
- 🇫🇮
GSK Investigational Site, Turku, Finland